|
 The message for policymakers is that pre-exposure prophylaxis (PrEP)
use among injection drug abusers is effective, but very costly, said
study author Dr. Douglas Owens.
Even as part of a comprehensive screening and treatment program for
injection drug users, PrEP would not be cost effective, Owens, of
Stanford University in California, and his colleagues write in the
Annals of Internal Medicine, April 25.
Currently, the daily pill known as Truvada, manufactured by Gilead,
is the only form of PrEP approved by the U.S. Food and Drug
Administration. The pill contains the drugs tenofovir and
emtricitabine.
Researchers reported in 2013 that Truvada reduced HIV incidence
among injection drug users in Thailand by about 49 percent.
Owens and his colleagues write that while less than 1 percent of
U.S. adults abuse injection drugs, about 10 percent of new HIV
infections occur in that group.
Using a computer simulation, the researchers estimated that
providing PrEP to a quarter of injection drug users in conjunction
with frequent screenings and prompt treatment for new infections
would prevent about 26,700 new infections in the U.S. over the next
two decades and prevent about 6,300 deaths from AIDS.
The combination approach would reduce HIV prevalence in injection
drug users 14 percent by 2035.
The cost of such a program over those two decades would be about $44
billion under current prices. The yearly cost of $2.2 billion
represents about 9 percent of the allocated domestic HIV/AIDS funds
in the 2015 federal budget.
The program would also cost about $253,000 per quality year of life
(QALY) gained, which far surpasses the widely accepted limit of
$100,000 per QALY of cost effectiveness.
The cost per QALY would meet that threshold if the price of Truvada,
which currently sits at about $10,000 per year, falls by 65 percent,
they note.
[to top of second column] |
In an editorial, Dr. Rochelle Walensky highlights the complexity of
trying to prevent a chronic disease - that is, HIV - in people who
are at risk of death from overdoses.
"What good is preventing HIV if we do not first save that life at
HIV risk?" she writes.
Walensky suggests resources may be better spent on improving access
to naloxone therapy, medical insurance, detoxification programs,
methadone therapy and needle exchanges.
Owens also said it's important to look at the broad range of
services available to injection drug users.
"(PrEP) can certainly provide extensive health benefit, but . . .
it’s important to look at all the services you can provide to this
group," he said.
For example, the researchers found, needle exchanges cost $4,500 to
$34,000 per QALY gained.
SOURCE: http://bit.ly/1Wqpm7G and http://bit.ly/1YUeM7W
Ann Intern Med 2016.
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
